UPLIZNA is the only approved monotherapy for neuromyelitis optica spectrum disorder (NMOSD) with twice-yearly maintenance dosing1-4
INFUSION SCHEDULE
- Administer all vaccinations at least 4 weeks prior to initiation of UPLIZNA1
- Check Ig levels and blood cell count, screen for hepatitis infection and active infections (incl. tuberculosis) prior to first dose1
- Administer a corticosteroid, an antihistamine, and an anti-pyretic 30-60 minutes prior to administration to reduce infusion reactions and attacks1
TREATMENT COMPARISON
See how the UPLIZNA infusion schedule compares to other approved therapies in NMOSD.
| Approved NMOSD treatment | UPLIZNA (inebilizumab)1 |
SOLIRIS (eculizumab)3 |
ENSPRYNG (satralizumab)4 |
| Mechanism of action | CD19+ B-cell depletion | Complement (anti-C5) | Anti-IL-6R |
| Initial phase | 2 doses over 2 weeks | 4 doses over 4 weeks | 3 doses over 4 weeks |
| Maintenance phase | 2 doses per year | 26 doses per year | 13 doses per year |
| Mode of administration | IV infusion | IV infusion | SC injection |
| Duration of administration | approx. 90 min/infusion | approx. 25-45 min/infusion | immediate injection |
IV: intravenous; SC: subcutaneous.
Scientific e-Service
Stay up-to-date on UPLIZNA with the latest scientific news, updates, and materials on treating NMOSD